UBS Initiates Coverage On Solid Biosciences with Buy Rating, Announces Price Target of $20
Benzinga Newsdesk 2 weeks ago
Analyst RatingsNewsInitiationPrice Target
UBS analyst Joon Lee initiates coverage on Solid Biosciences (NASDAQ:SLDB) with a Buy rating and announces Price Target of $20.
UBS analyst Joon Lee initiates coverage on Solid Biosciences (NASDAQ:SLDB) with a Buy rating and announces Price Target of $20.